| Labcorp

September 12, 2022

Comprehensive analysis of the association between RAS mutation and immune checkpoint marker expression

ESMO 2022 -- Revealing the relationship between RAS mutation and the expression level of the immune checkpoint molecules can guide potential combinations of treatments.

September 13, 2022

Spontaneous Neoplasms in the Uterus, Vagina and Cervix of Mice from Carcinogenicity Studies

ESTP Congress 2022 -- Carcinogenicity studies are important in identifying tumorigenic potential in animals as part of the risk assessment for new drugs. Historical control data incidences can be useful when selecting and assessing the suitability of an animal model.

September 13, 2022

Spontaneous Neoplasms in the Uterus, Vagina and Cervix of Rats from 104-Week Carcinogenicity Studies

ESTP Congress 2022 -- Carcinogenicity studies are important in identifying tumorigenic potential in animals as part of the risk assessment for new drugs. Historical control incidences are important considerations when interpreting data and useful when selecting and assessing the suitability of an animal model.

September 16, 2022

Using telemedicine and local treatment to avoid Australian interstate travel quarantines

A China-based biotech company with a Phase Ia/Ib solid tumor oncology trial running in Australia needed a creative solution to maintain study participant engagement. One participant needed to travel from their home state (Tasmania) to another state (Victoria) where the investigator site was located.

September 19, 2022

Cell and Gene Therapy - High Quality and Safety from Vein to Vein: CMC Testing for CAR T-Cell Therapies

Chemistry, Manufacturing and Control (CMC) testing is an integral part of the CAR T-cell clinical journey during vector production and T-cell modification. These tests, mandated by the FDA and other regulatory agencies, uphold the safety, purity and potency of the product before being administered to the patient.

September 20, 2022

Utilizing health economic insights to inform product development and secure market access

We are your source for strategic HEOR services to support successful market access activities. A winning market access strategy requires early and ongoing consideration of the health economic and outcomes research (HEOR) needs for your product.

September 22, 2022

Characterizing the effector functions of therapeutic antibodies

Understand the Fc region of your antibody product, so that you can assess the impact on immunology, safety and efficacy. Using a risk-based approach, find out the most efficient way to test functionality relevant to the stage of drug development.

September 26, 2022

Released N-Glycan Analysis of the Fc-Fusion Protein Aflibercept with Additional Site-Specific Population and Occupancy Analysis

CASSS MS 2022 -- Glycosylation is a common PTM and is formed during the production and manufacture of a therapeutic product. Glycans play a significant role in therapeutic proteins and require confident quantitative analysis.

September 26, 2022

Assessment of Immunogenicity in SARS-CoV-2 Naïve and Convalescent Subjects Following COVID-19 Vaccination

WRIB 2022 -- Active vaccination leads to successful priming of adaptive immune responses, resulting in the development of antigen-specific T and B effector cells. Upon encountering the same antigen (by booster vaccine or exposure to infection), these effector lymphocytes proliferate and undergo clonal expansion and differentiation.

October 10, 2022

Designing a high-touch, low-burden pediatric vaccine study with powerful digital solutions

Labcorp's diligence in engaging investigator sites, providing comprehensive decentralized solutions accommodating the stretch timeline goals has helped the sponsor to run this powerful pediatric vaccine study. Labcorp Drug Development impressed the sponsor with a range of powerful digital solutions.

管理您的健康

疾病与治疗领域

治疗模式与方法

科学实验室学科

实验室

行业